Our Phase 3 #clinicaltrial of #buntanetap for early #AlzheimersDisease is officially underway, with the first two patients being entered today! This is a significant step forward - not just for Annovis, but for the entire Alzheimer's community - brining us closer to delivering a much-needed treatment. We would like to thank everyone whose faith and support made this trial possible. For more information, check our news release https://lnkd.in/e7fs_va5 For details about the study, please visit https://lnkd.in/emfAsBzg #Alzheimers #Annovis #dementia #AD
Annovis Bio, Inc.
生物技术研究
Malvern，Pennsylvania 3,345 位关注者
It’s time for a new direction in treating Alzheimer’s, Parkinson’s and related neurodegenerative diseases.
关于我们
At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.
- 网站
-
https://annovisbio.com/
Annovis Bio, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Malvern，Pennsylvania
- 类型
- 私人持股
- 创立
- 2008
- 领域
- Neurodegeneration、Alzheimer’s、Parkinson’s、Alzheimer’s in Down Syndrome、Axonal Transport、Traumatic Brain Injury、APP、tau、aSYN、neurotoxic proteins、APP/Ab (APP)、tau/phospho-tau和a-Synuclein (a-SYN)
地点
-
主要
获取路线
101 Lindenwood Dr.
Suite #225
US，Pennsylvania，Malvern，19355
Annovis Bio, Inc.员工
动态
-
Next week, our CEO,?Maria Maccecchini, Ph.D., will attend the?13th Alzheimer’s & Parkinson’s Drug Development Summit, where she will participate in a panel discussion on the future of #Parkinsons treatment. We look forward to these critical discussions at the summit, where biotech and pharma leaders come together to advance the discovery of new therapeutic targets for neurodegenerative diseases. More at https://lnkd.in/egdJ7_hc
-
-
Join us next week on February 27 at 4:30 PM ET?for a live forum?with our CEO, Maria Maccecchini, Ph.D.?She’ll be answering questions from patients, families, and caregivers, providing insights into our progress. ?? Submit your questions in advance?to [email protected] ?? Register here:?https://lnkd.in/ePQt7r9a ?? Full release:?https://lnkd.in/ewqgcaCV We look forward to an engaging discussion—see you there!
-
-
We are proud to announce the granting of a U.S. #patent for the use of #buntanetap in acute #brain and #nerve injuries. This patent complements our existing IP protection for acute indications in Europe, Japan, and beyond, now ensuring global coverage. Learn more at: https://lnkd.in/erEK3h3S
-
-
We are excited to announce that the FDA has accepted the final protocol for our pivotal Phase 3 Alzheimer's study.?The next phase will now include a single 6/18-month study instead of the originally proposed two separate trials, accelerating our efforts in advancing buntanetap. Find more information at: https://lnkd.in/esg9kCDT #Annovis #clinicaltrials #biotech #Alzheimers
-
-
As we celebrate this holiday season, we want to express our gratitude to everyone who has supported us throughout the year. Whether you're a patient, caregiver, or advocate, your belief in our mission is the greatest gift. Thank you for being part of our journey. We’re looking forward to a new year filled with progress and hope. Team Annovis is wishing you and your loved ones a joyful holiday season!
-
-
As the year draws to a close, we reflect on key milestones Annovis achieved this fall. A successful meeting with the FDA cleared the path for our pivotal Phase 3 AD trial, which will begin early next year. We expanded our IP portfolio, welcomed a new member to our clinical team, and shared our latest findings at several conferences and workshops. The road to developing a new treatment for neurodegenerative diseases is challenging, but we are proud of our progress which makes us well-prepared for what's to come. We are deeply grateful for the continued support of our community and look forward to sharing more updates as we advance our efforts in 2025. #AnnovisBio #Alzheimers #Parkinsons #biotech
-
Annovis Bio will host a year-end investor webcast on December 11, at 4:30 pm EST. Our CEO, Maria L. Maccecchini, PhD, will present the company's updates, share the strategic outlook for 2025, and conclude with a Q&A session. Participants are encouraged to submit their questions in advance. More information at https://lnkd.in/e77ckvP5
-
-
Annovis Bio will host a year-end investor webcast on December 11, at 4:30 pm EST. Our CEO, Maria L. Maccecchini, PhD, will present the company's updates, share the strategic outlook for 2025, and conclude with a Q&A session. Participants are encouraged to submit their questions in advance. More information at https://lnkd.in/e77ckvP5
-
-
We look forward to it!
Acumen Pharmaceuticals, Inc., Johnson & Johnson, Annovis Bio, Inc., AbbVie, Lexeo Therapeutics, and others are set to showcase cutting-edge advancements in ?????? ?????????????? ?????? ???????????????????? transforming the neurodegenerative treatment landscape. Join 150+ industry pioneers at the ???????? ??????????????????’?? & ??????????????????’?? ???????? ?????????????????????? ???????????? to benchmark progress and discuss innovative programs targeting tau, 15-Lipoxygenase, mitochondrial dysfunction, TDP-43 and more. Early bird registration expires this Friday: https://ter.li/vgrpr9 #amyloid #tau #alphasynuclein #neuroinflammation #mitochondria #TDP43
-